Reblozyl is the first and only therapy to demonstrate superiority compared to an erythropoiesis stimulating agent (ESA) in MDS-related anemia
The groundbreaking, uniquely robust Robert A. Winn Diversity in Clinical Trials Award Program is on track to train more than 500 individuals from diverse backgrounds by 2027
This is the first CAR T cell therapy application filed for the second-line treatment of R/R LBCL in Japan
The consultations are virtual and they have launched the Diabetes Reversal Programme to address the issue
The recommendation is based on positive results from the pivotal Phase 3 CheckMate -649 trial in which Opdivo plus chemotherapy demonstrated superior overall survival versus chemotherapy
KarXT, Karuna’s lead asset, is a potential first-in-class treatment for Schizophrenia
Seeks partnership between government and private medical colleges for providing superior medical education
Allam was serving recently as the CEO at Public Investment Fund
Dasatinib Tablet is indicated for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive
Opdivo-based treatments are now approved for five indications in upper gastroesophageal cancers
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)